Edition:
India

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

69.10EUR
17 Jan 2018
Change (% chg)

€0.80 (+1.17%)
Prev Close
€68.30
Open
€68.02
Day's High
€69.54
Day's Low
€67.80
Volume
447,558
Avg. Vol
367,556
52-wk High
€79.05
52-wk Low
€56.55

Select another date:

Tue, Jan 9 2018

BRIEF-UCB Announces That EMA Has Approved Label Change For Cimzia

* LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING Source text : http://bit.ly/2Fe7JUV Further company coverage: (Gdynia Newsroom)

BRIEF-UCB Announces European Medicines Agency Accepts Filing For Evenity

* EUROPEAN MEDICINES AGENCY ACCEPTS FILING FOR EVENITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-UCB Announces Positive Top Line Results Of Phase 2b Bimekizumab Study

* BIMEKIZUMAB DEMONSTRATES IMPRESSIVE JOINT AND SKIN RESPONSES FOR PSORIATIC ARTHRITIS PATIENTS‍​

BRIEF-UCB Bimekizumab Announces Results For Phase 2b Of BE Agile Study ‍​

* BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS‍​

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

BRIEF-UCB 9-month revenue up at 3.3 billion euros, 2017 outlook increased

* 9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION

BRIEF-‍Partners Connected Health and UCB announce epilepsy partnership​

* ‍PARTNERS CONNECTED HEALTH AND UCB ANNOUNCE COLLABORATION TO DEVELOP HEALTHCARE SOLUTIONS TO SUPPORT PEOPLE LIVING WITH EPILEPSY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use

* ANTI-EPILEPTIC DRUG VIMPAT (LACOSAMIDE) RECEIVES EU APPROVAL FOR PAEDIATRIC USE

BRIEF-UCB's Briviact approved by FDA as monotherapy treatment of partial-onset seizures in adults

* NEW INDICATION FOR BRIVIACT (BRIVARACETAM): UCB'S NEWEST ANTIEPILEPTIC DRUG APPROVED BY FDA AS MONOTHERAPY TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-UCB and Amgen announce detailed results from the phase 3 ARCH study

* ANNOUNCED ON MONDAY, TOGETHER WITH AMGEN , DETAILED RESULTS FROM THE PHASE 3 ARCH STUDY

Select another date: